Trial reportInternational ophthalmology2025
Effects of a propylene glycol-hydroxypropyl guar nanoemulsion in patients with mild to moderate dry eye disease.
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry eye disease (DED) is a common inflammatory disease of the eye surface that significantly affects quality of life. The present study investigated the effect of a propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion on objective non-invasive ocular surface status markers in individuals with mild to moderate dry eye disease.
methodsA nonrandomized clinical trial in fifty eyes from 25 healthy subjects with mild to moderate DED who applied one drop of PG-HPG nanoemulsion to each eye twice a day for three months. The primary outcomes measured changes in tear film osmolarity and meibography scores from baseline to three months.
resultsThere were statistically significant changes in meibography scores (p < 0.0001) and osmolarity (p = 0.0066) from baseline to three months. The average osmolarity decreased by approximately 6.17 units from baseline to three months. No statistically significant changes were observed in NIAVG, Schirmer's test, or NIBUT from baseline to three months.
conclusionsPG-HPG Nano-emulsion produced changes in objective non-invasive ocular surface status markers, including a reduction in meibography scores and tear film osmolarity at three months, further clinical studies on the effectiveness of PG-HPG against a comparator are to expand the evidence of its effectiveness as a therapeutic option and its effects on patient quality of life in DED management.
Indexed as
Identifiers
40694228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.